Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

描述（由申请人提供）：前列腺癌（PCa）是男性癌症患者的第二大杀手。最终的测试是基于经直肠超声引导穿刺活检和固定前列腺组织的组织学检查。这种传统的诊断程序是侵入性的，由于小的采样体积，错过了30%的癌症病例。此外，由于诊断侵袭性癌症的特异性低，它导致对患者的过度治疗。为了满足这一迫切需求，Vibronix，Inc.及其在普渡大学和印第安纳州大学医学院的研究伙伴提出开发一种光谱振动光声断层扫描（VPAT）系统，用于使用胆固醇酯积累作为生物标志物的PCa诊断。作为一家总部位于印第安纳州的小企业，Vibronix，Inc.公司的长期目标是将VPAT技术从台式应用到床边。该STTR项目的中心假设是VPAT系统可以测量完整前列腺组织中肿瘤的大小。Vibronix公司沿着其研究伙伴组成了一个跨学科小组来检验这一假设。Ji-Xin Cheng博士（PI）首次证明CE蓄积是PCa的标志物。他的实验室还展示了第一个VPAT系统6。Liang Cheng博士（医学博士）是印第安纳州大学医学院（IUSM）病理学系的教授，将对乳房切除术样本进行病理学分级。Timothy Masterson博士（医学博士）是泌尿外科助理教授，专门治疗成人泌尿生殖系统癌症。所提出的假设可以通过以下具体目标来检验：（1）演示具有3 cm成像深度的小型化VPAT系统。(2)演示使用CE作为生物标志物的完整前列腺的光谱VPAT成像，以区分正常和癌性前列腺组织，并测量组织体积。可验证：在成功设计和评估的经直肠光谱VPAT系统，我们将产生一个新的成像技术，用于测量前列腺肿瘤体积在一个完整的前列腺使用CE作为生物标志物。这一进展将为II期研究奠定基础，其中将进行体内VPAT成像，CE积累将与PCa的侵袭性相关。最终，我们的VPAT技术，以微创的方式，将帮助医生客观地诊断PCa，并决定是否需要进行前列腺切除术。

DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the No. 2 killer among male cancer patients. The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues. This conventional diagnostic procedure is invasive, missing 30% cases of cancer due to small sampling volume. Moreover, it leads to an overtreatment of patients due to low specificity in diagnosing aggressive cancers. To address this pressing need, Vibronix, Inc. and its research partners at Purdue University and Indiana University School of Medicine propose to develop a spectroscopic vibrational photoacoustic tomography (VPAT) system for PCa diagnosis using cholesteryl ester accumulation as biomarker. As an Indiana-based small business, Vibronix, Inc.'s long-term goal is to bring the VPAT technology from bench top to bedside. The central hypothesis of this STTR project is that the VPAT system can measure the size of the tumor in intact prostate tissue. Vibronix, Inc. along with its research partners have formed an interdisciplinary team to test this hypothesis. Dr. Ji-Xin Cheng (PI) the first to demonstrate CE accumulation as a marker for PCa. His lab also demonstrated the first VPAT system 6. Dr. Liang Cheng (MD) is a professor in Department of Pathology in Indiana University School of Medicine (IUSM) and will perform pathological grading of the prostatectomy samples. Dr. Timothy Masterson (MD) is an Assistant Professor of Urology and specializes in the treatment of adult genitourinary cancers. The proposed hypothesis can be tested through the following specific aims: (1) Demonstrate a miniaturized VPAT system with an imaging depth of 3 cm. (2) Demonstrate spectroscopic VPAT imaging of intact prostate gland using CE as a biomarker to differentiate normal and cancerous prostate tissues, and the measurement of the tissue volume. Deliverable: Upon successful design and evaluation of the transrectal spectroscopic VPAT system, we will have generated a new imaging technology for measure the prostate tumor volume in an intact prostate gland using CE as a biomarker. This advance will pave the foundation for a phase II study in which in vivo VPAT imaging will be performed and CE accumulation will be correlated with aggressiveness of PCa. Eventually, our VPAT technology, in a minimally invasive manner, would assist a physician to diagnose PCa objectively and to decide whether prostatectomy surgery is needed.